An interventional study of Eminoplasty with patient specific ultrahigh molecular weight polyethylene onlay implant in Recurrent Dislocation of Temporomandibular Joint (Disorder), sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 48 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Does patient specific Ultra-High Molecular Weight Polyethylene implant eminoplasty will decrease maximum interincisal distance, provide better soft tissue response and post-operative patient satisfaction than patient specific Titanium eminoplasty in treatment of chronic condylar dislocation?
Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Eminoplasty will be done for patient with chronic condylar dislocation using specific ultrahigh molecular weight polyethylene implants
Device: Eminoplasty with patient specific ultrahigh molecular weight polyethylene onlay implant
eminoplasty with patient specific titanium onlay implant
Device: Eminoplasty with patient specific ultrahigh molecular weight polyethylene onlay implant
Eminoplasty will be done for patient with chronic condylar dislocation using patient specific ultrahigh molecular weight polyethylene
Difference in maximal inter incisal distance between pre-operative and post-operative (mm)
using a caliper difference between preoperative and postoperative maximal interincisal opening is recorded (mm)
Time frame: 6 months
patient pain
IN terms of (VAS) visual analogue scale (0-10), Visual Analog Scale (VAS) is a 0-10 scale used to measure pain intensity, where 0 represents no pain and 10 represents the worst possible pain.The Visual Analog Scale (VAS) is a validated, subjective tool for assessing pain intensity in both acute and chronic conditions. It consists of a continuous line, usually 10 cm (100 mm) long, anchored at one end with "no pain" (0) and at the other end with "worst imaginable pain" (10). Patients indicate their pain by marking a point along the line that best represents their current pain level. The distance from the "no pain" end is measured in centimeters or millimeters to quantify pain intensity 0: No pain,1-3: Mild pain, usually tolerable and not interfering significantly with daily activity, 4-6: Moderate pain, noticeable and may limit some activities,7-9: Severe pain, significantly limiting daily activities and requiring intervention,10: Worst possible pain, unbearable need urgent management
Time frame: 6 months
Plan to share: Yes
Supporting information: Study protocol
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University